Hospital groups sue HHS seeking 340B price transparency now

Sep 11, 2018 - 02:55 PM

The AHA, Association of American Medical Colleges, America’s Essential Hospitals, 340B Health and three hospital systems today asked a federal court to order the Department of Health and Human Services to make effective within 30 days a final rule requiring drug companies to disclose the ceiling price for 340B outpatient drugs. HHS has delayed five times the effective date for the rule, required by Congress in 2010. To ensure accuracy and compliance with the 340B drug savings program, the rule also describes how ceiling prices must be calculated and would allow the federal government to levy civil monetary penalties against drug companies that intentionally overcharge 340B providers. 

“As prescription drug prices continue to skyrocket, the 340B program is as crucial as ever in helping hospitals and health systems provide access to health care services for vulnerable patients and communities,” said AHA President and CEO Rick Pollack. “Our lawsuit will promote the transparency and accuracy that the government has found lacking and hold price gouging drug companies accountable.” 

The associations are joined in the suit by hospital plaintiffs Rutland Regional Medical Center in Rutland, Vt.; Genesis HealthCare System in Zanesville, Ohio; and Kearny County Hospital in Lakin, Kan. 
 

Related News Articles

Headline
HHS announces revised 340B Rebate Model Pilot Program; see AHA’s statement shared with media 
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
Court rules that companies may not impose 340B rebate model without HHS approval
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
AHA challenges HRSA’s burden estimate for proposed 340B rebate model
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
AHA urges court to reject AbbVie bid to change 340B program rules
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
HRSA announces 340B program sales reached $100 billion in CY 2025
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…
Perspective
Keeping Patient Access Front and Center in Washington
Public
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…